Skip to content
2000
Volume 22, Issue 7
  • ISSN: 1389-2010
  • E-ISSN: 1873-4316

Abstract

In recent years, extensive attention has been given to the generation of new classes of ligand- specific binding proteins to supplement monoclonal antibodies. A combination of protein engineering and display technologies has been used to manipulate non-human antibodies for humanization and stabilization purposes or even the generation of new binding proteins. Engineered protein scaffolds can now be directed against therapeutic targets to treat cancer and immunological disorders. Although very few of these scaffolds have successfully passed clinical trials, their remarkable properties such as robust folding, high solubility, and small size motivate their employment as a tool for biology and applied science studies. Here, we have focused on the generation of new non-Ig binding proteins and single domain antibody manipulation, with a glimpse of their applications.

Loading

Article metrics loading...

/content/journals/cpb/10.2174/1389201021999200824101035
2021-06-01
2025-07-13
Loading full text...

Full text loading...

/content/journals/cpb/10.2174/1389201021999200824101035
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test